NO943653L - Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon - Google Patents
Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjonInfo
- Publication number
- NO943653L NO943653L NO943653A NO943653A NO943653L NO 943653 L NO943653 L NO 943653L NO 943653 A NO943653 A NO 943653A NO 943653 A NO943653 A NO 943653A NO 943653 L NO943653 L NO 943653L
- Authority
- NO
- Norway
- Prior art keywords
- prevention
- treatment
- monoclonal antibodies
- hiv
- neutralizing monoclonal
- Prior art date
Links
- 208000031886 HIV Infections Diseases 0.000 title abstract 2
- 230000003472 neutralizing effect Effects 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title abstract 2
- 208000037357 HIV infectious disease Diseases 0.000 title 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 229940072221 immunoglobulins Drugs 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86170192A | 1992-04-01 | 1992-04-01 | |
| PCT/US1993/002629 WO1993019785A1 (en) | 1992-04-01 | 1993-03-23 | Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO943653D0 NO943653D0 (no) | 1994-09-30 |
| NO943653L true NO943653L (no) | 1994-11-30 |
Family
ID=25336532
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO943653A NO943653L (no) | 1992-04-01 | 1994-09-30 | Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0577243A3 (sk) |
| JP (1) | JPH06217791A (sk) |
| KR (1) | KR950700761A (sk) |
| CN (1) | CN1081716A (sk) |
| AU (2) | AU3928593A (sk) |
| BG (1) | BG99074A (sk) |
| CA (1) | CA2093099A1 (sk) |
| CZ (1) | CZ239694A3 (sk) |
| FI (1) | FI944561A0 (sk) |
| HU (1) | HUT70461A (sk) |
| IL (1) | IL105145A0 (sk) |
| MX (1) | MX9301858A (sk) |
| NO (1) | NO943653L (sk) |
| NZ (1) | NZ251582A (sk) |
| RU (1) | RU94045907A (sk) |
| SK (1) | SK116294A3 (sk) |
| WO (1) | WO1993019785A1 (sk) |
| YU (1) | YU22693A (sk) |
| ZA (1) | ZA932308B (sk) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003500003A (ja) * | 1998-10-30 | 2003-01-07 | ノボザイムス アクティーゼルスカブ | 低いアレルゲン性のタンパク質変異型 |
| US7560529B2 (en) | 2001-04-24 | 2009-07-14 | FDS Pharma | Method for producing catalytic antibodies (variants), antigens for immunization and nucleotide sequence |
| RU2221873C2 (ru) * | 2001-04-24 | 2004-01-20 | Закрытое акционерное общество "АСГЛ-Фармацевтические Инновации" | Способ получения каталитических антител (варианты), антигены для иммунизации и нуклеотидная последовательность |
| FR2844455B1 (fr) * | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
| JP4922613B2 (ja) * | 2003-02-20 | 2012-04-25 | 一般財団法人化学及血清療法研究所 | モノクローナル抗体製剤の奏効性を向上させる方法 |
| JP2010536885A (ja) * | 2007-08-24 | 2010-12-02 | ノバルティス アーゲー | Ｖ３ループに改変を有するｈｉｖｅｎｖタンパク質 |
| KR101687841B1 (ko) | 2008-12-09 | 2016-12-19 | 길리애드 사이언시즈, 인코포레이티드 | 톨-유사 수용체의 조절제 |
| US10421803B2 (en) | 2014-01-31 | 2019-09-24 | The Rockefeller University | Broadly neutralizing glycan-dependent 8ANC195 antibody variants that bind to an epitope spanning both HIV-1 Env subunits |
| CA2954056C (en) * | 2014-07-11 | 2020-04-28 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of hiv |
| JP2017526730A (ja) | 2014-09-16 | 2017-09-14 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｏｌｌ様受容体モジュレーターの固体形態 |
| WO2021227138A1 (zh) * | 2020-05-09 | 2021-11-18 | 江苏省疾病预防控制中心(江苏省公共卫生研究院) | 针对新型冠状病毒的单克隆抗体或其抗原结合部分 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1339857C (en) * | 1987-05-29 | 1998-05-05 | Cecily Rou-Yun Sun | Monoclonal antibodies to gp120 which neutraleze hiv-1 |
| EP0311228A3 (en) * | 1987-10-09 | 1990-05-02 | Repligen Corporation | Recombinant polypeptides and their uses, including assay for aids virus |
| CA2058630A1 (en) * | 1989-06-05 | 1990-12-06 | Charles F. Scott, Jr. | Human monoclonal antibodies to hiv-1 mn gp 120 |
| EP0535154A4 (en) * | 1990-06-15 | 1993-12-01 | New York University | Heterohybridomas producing human monoclonal antibodies to hiv-1 |
| JPH07505051A (ja) * | 1992-01-29 | 1995-06-08 | アメリカ合衆国 | Ｈｉｖ−１ｅｎｖ及びｎｅｆタンパク質に対して局部的相同性を有するタンパク質，ａａｍｐ−１ |
-
1993
- 1993-03-23 SK SK1162-94A patent/SK116294A3/sk unknown
- 1993-03-23 AU AU39285/93A patent/AU3928593A/en not_active Abandoned
- 1993-03-23 HU HU9402824A patent/HUT70461A/hu unknown
- 1993-03-23 WO PCT/US1993/002629 patent/WO1993019785A1/en not_active Application Discontinuation
- 1993-03-23 RU RU94045907/13A patent/RU94045907A/ru unknown
- 1993-03-23 CZ CZ942396A patent/CZ239694A3/cs unknown
- 1993-03-23 NZ NZ251582A patent/NZ251582A/en unknown
- 1993-03-24 IL IL105145A patent/IL105145A0/xx unknown
- 1993-03-31 EP EP9393302546A patent/EP0577243A3/en not_active Ceased
- 1993-03-31 MX MX9301858A patent/MX9301858A/es unknown
- 1993-03-31 CA CA002093099A patent/CA2093099A1/en not_active Abandoned
- 1993-03-31 CN CN93105210A patent/CN1081716A/zh active Pending
- 1993-03-31 ZA ZA932308A patent/ZA932308B/xx unknown
- 1993-03-31 AU AU35630/93A patent/AU658987B2/en not_active Ceased
- 1993-04-01 JP JP5098474A patent/JPH06217791A/ja active Pending
- 1993-04-01 YU YU22693A patent/YU22693A/sh unknown
-
1994
- 1994-09-28 BG BG99074A patent/BG99074A/xx unknown
- 1994-09-30 KR KR1019940703497A patent/KR950700761A/ko not_active Application Discontinuation
- 1994-09-30 FI FI944561A patent/FI944561A0/fi unknown
- 1994-09-30 NO NO943653A patent/NO943653L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| FI944561A (fi) | 1994-09-30 |
| AU658987B2 (en) | 1995-05-04 |
| KR950700761A (ko) | 1995-02-20 |
| SK116294A3 (en) | 1996-11-06 |
| AU3928593A (en) | 1993-11-08 |
| FI944561A0 (fi) | 1994-09-30 |
| RU94045907A (ru) | 1996-11-10 |
| NZ251582A (en) | 1997-07-27 |
| CZ239694A3 (en) | 1995-07-12 |
| BG99074A (en) | 1995-11-30 |
| EP0577243A2 (en) | 1994-01-05 |
| HUT70461A (en) | 1995-10-30 |
| CN1081716A (zh) | 1994-02-09 |
| IL105145A0 (en) | 1993-07-08 |
| NO943653D0 (no) | 1994-09-30 |
| JPH06217791A (ja) | 1994-08-09 |
| EP0577243A3 (en) | 1994-11-02 |
| WO1993019785A1 (en) | 1993-10-14 |
| AU3563093A (en) | 1993-10-07 |
| HU9402824D0 (en) | 1994-11-28 |
| MX9301858A (es) | 1994-03-31 |
| YU22693A (sh) | 1997-01-08 |
| CA2093099A1 (en) | 1993-10-02 |
| ZA932308B (en) | 1994-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE330631T1 (de) | Antikörperfragmente zur lokalen behandlung von augenerkrankungen | |
| FR12C0004I2 (fr) | Anticorps contre l'antigene ctla-4 humain et utilisation | |
| ATE512224T1 (de) | Rekonstituierter menschlicher anti-hm.1 antikörper | |
| DK0626447T3 (da) | Monoklonale antistoffer og Fv, som er specifikke for CD2-antigen | |
| PT712863E (pt) | Anticorpos monoclonais humanizados e quimericos que reconhecem o receptor do factor de crescimento epidermico (egf-r); utilizacao diagnostica e terapetica | |
| ATE373712T1 (de) | Natürlicher menschlicher antikörper | |
| DK0666868T3 (da) | Anvendelse af anti-VEGF-antistoffer til behandling af cancer | |
| PT699237E (pt) | Fvs de cadeia anti-egfr e anticorpos anti-egfr | |
| EP0671920A4 (en) | AN ANTI-IDIOTYPICAL ANTIBODY AND ITS USE IN THE DIAGNOSIS AND THERAPY OF HIV-RELATED DISEASES. | |
| NO943653L (no) | Rekombinante, humane HIV-nöytraliserende monoklonale antistoffer for forebyggelse og behandling av HIV-infeksjon | |
| SE8703225L (sv) | Monoklonala antikroppar och peptider anvendbara vid behandling och diagnostisering av hiv-infektioner | |
| CY2583B2 (en) | Reshaped monoclonal antibodies against an immunoglobulin isotype | |
| MC2308A1 (fr) | Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine | |
| DK0546076T3 (da) | Anvendelse af anti-ICAM antistoffer til fremstilling af et lægemiddel til behandling af endotoksiskshock | |
| ATE148348T1 (de) | Behandlung von einer autoimmun-krankheit | |
| SE9201281D0 (sv) | New human monoclonal antibodies, and a method for preparation thereof | |
| ES2000615A6 (es) | Procedimiento para la preparacion del anticuerpo monoclonal designado como mak 436-15 del isotipo igg3" | |
| KR890016165A (ko) | 수도모나스 아에루기노사(Pseudomonas aeruginosa)에 대한 모노클로날 항체, 이의 제조방법 및 용도 | |
| NO984851L (no) | DHEA kombinasjonsterapi | |
| NO924803L (no) | Tumor-relatert monoklonalt antistoff 88bv59 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |